miR‑30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein

Huang,Ya‑Qiang; Ling,Xiao‑Hui; Yuan,Run‑Qiang; Chen,Zhi‑Yun; Yang,Sheng‑Bang; Huang,Hong‑Xing; Zhong,Wei‑De; Qiu,Shao‑Peng

doi:10.3892/mmr.2017.6910

miR‑30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein

Authors:
- Ya‑Qiang Huang
- Xiao‑Hui Ling
- Run‑Qiang Yuan
- Zhi‑Yun Chen
- Sheng‑Bang Yang
- Hong‑Xing Huang
- Wei‑De Zhong
- Shao‑Peng Qiu
View Affiliations

Affiliations: Department of Urology, Zhongshan Hospital of Sun Yat‑sen University, Zhongshan, Guangdong 528400, P.R. China, Reproductive Medicine Centre, Huizhou Municipal Central People's Hospital, Huizhou, Guangdong 516001, P.R. China, Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China, Department of Urology, First Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China
Published online on: July 4, 2017 https://doi.org/10.3892/mmr.2017.6910
Pages: 2431-2438
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Our previous study revealed that microRNA (miR) ‑30c represents a potential tumor suppressor gene, the expression of which is associated with decreased oncogenic potential in prostate cancer (PCa) cell lines. However, the functional role and underlying mechanisms of miR‑30c in PCa remain to be fully elucidated. Reverse transcription‑quantitative polymerase chain reaction and immunohistochemical analysis were used to detect the expression levels of alternative splicing factor/splicing factor 2 (ASF/SF2) in PCa tissues. A luciferase reporter assay was used to investigate whether ASF/SF2 may be a direct target gene of miR‑30c. In addition, the effects of miR‑30c on the proliferation and apoptosis of PCa cell lines were examined, following transfection with miR‑30c mimics. Furthermore, correlation analysis was performed to investigate the relationship between the expression of miR‑30c and ASF/SF2 and various clinicopathological parameters of patients with PCa. The present results demonstrated that PCa tissues exhibited higher levels of alternative splicing factor/splicing factor 2 (ASF/SF2), compared with normal tissues. In addition, miR‑30c was revealed to targete the 3'‑untranslated region of the ASF/SF2 gene, causing a decrease in the mRNA and protein levels of ASF/SF2. Furthermore, miR‑30c was reported to decrease cell proliferation, increase the percentage of cells in the G1 cell cycle phase, and promote apoptosis through the inhibition of ASF/SF2. Following correlation analysis using patient samples, the expression of ASF/SF2 was revealed to be tightly correlated with the pathological stage of PCa and biochemical recurrence (BCR). In addition, patients with PCa exhibiting low expression levels of miR‑30c and high expression of ASF/SF2 had significantly lower rates of BCR‑free survival. In conclusion, the present study suggested that the tumor suppressor miR‑30c may be involved in PCa tumorigenesis, possibly via targeting ASF/SF2. The combined analysis of the expression of ASF/SF2 and miR‑30c may be a valuable tool for early prediction of BCR in patients with PCa following radical prostatectomy.

View Figures

View References

1	Kakehi Y: Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn J Clin Oncol. 33:1–5. 2003. View Article : Google Scholar : PubMed/NCBI
2	Santanam U, Banach-Petrosky W, Abate-Shen C, Shen MM, White E and DiPaola RS: Atg7 cooperates with Pten loss to drive prostate cancer tumor growth. Genes Dev. 30:399–407. 2016. View Article : Google Scholar : PubMed/NCBI
3	Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J, Rizvanov A, Heery DM, Mongan NP, Maitland NJ, et al: Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow. Cancer Res. 76:2453–2464. 2016. View Article : Google Scholar : PubMed/NCBI
4	Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G and Ye CJ: Genetic and epigenetic heterogeneity in cancer: A genome-centric perspective. J Cell Physiol. 220:538–547. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ulaganathan VK, Sperl B, Rapp UR and Ullrich A: Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site. Nature. 528:570–574. 2015. View Article : Google Scholar : PubMed/NCBI
6	Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V, et al: SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling. Cancer Cell. 31:436–451. 2017. View Article : Google Scholar : PubMed/NCBI
7	Wu Q, Song R, Ortogero N, Zheng H, Evanoff R, Small CL, Griswold MD, Namekawa SH, Royo H, Turner JM and Yan W: The RNase III enzyme DROSHA is essential for microRNA production and spermatogenesis. J Biol Chem. 287:25173–25190. 2012. View Article : Google Scholar : PubMed/NCBI
8	Kent OA and Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
9	Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, et al: MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 40:3689–3703. 2012. View Article : Google Scholar : PubMed/NCBI
10	Rane JK, Scaravilli M, Ylipää A, Pellacani D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T and Maitland NJ: MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Eur Urol. 67:7–10. 2015. View Article : Google Scholar : PubMed/NCBI
11	Alhasan AH, Scott AW, Wu JJ, Feng G, Meeks JJ, Thaxton CS and Mirkin CA: Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. Proc Natl Acad Sci USA. 113:10655–10660. 2016. View Article : Google Scholar : PubMed/NCBI
12	Li X, Wan X, Chen H, Yang S, Liu Y, Mo W, Meng D, Du W, Huang Y, Wu H, et al: Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer. Clin Cancer Res. 20:2312–2325. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ling XH, Han ZD, Xia D, He HC, Jiang FN, Lin ZY, Fu X, Deng YH, Dai QS, Cai C, et al: MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. Mol Biol Rep. 41:2779–2788. 2014. View Article : Google Scholar : PubMed/NCBI
14	Ling XH, Chen ZY, Luo HW, Liu ZZ, Liang YK, Chen GX, Jiang FN and Zhong WD: BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression. Oncol Lett. 11:2001–2008. 2016.PubMed/NCBI
15	Yu F, Deng H, Yao H, Liu Q, Su F and Song E: Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 29:4194–4204. 2010. View Article : Google Scholar : PubMed/NCBI
16	Martinez I, Cazalla D, Almstead LL, Steitz JA and DiMaio D: miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci USA. 108:522–527. 2011. View Article : Google Scholar : PubMed/NCBI
17	Zhao JJ, Lin J, Zhu D, Wang X, Brooks D, Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, et al: miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res. 74:1801–1813. 2014. View Article : Google Scholar : PubMed/NCBI
18	Pino I, Pío R, Toledo G, Zabalegui N, Vicent S, Rey N, Lozano MD, Torre W, García-Foncillas J and Montuenga LM: Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer. 41:131–143. 2003. View Article : Google Scholar : PubMed/NCBI
19	Zerbe LK, Pino I, Pio R, Cosper PF, Dwyer-Nield LD, Meyer AM, Port JD, Montuenga LM and Malkinson AM: Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre-mRNA processing. Mol Carcinog. 41:187–196. 2004. View Article : Google Scholar : PubMed/NCBI
20	de Miguel FJ, Sharma RD, Pajares MJ, Montuenga LM, Rubio A and Pio R: Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res. 74:1105–1115. 2014. View Article : Google Scholar : PubMed/NCBI
21	Anczuków O, Akerman M, Cléry A, Wu J, Shen C, Shirole NH, Raimer A, Sun S, Jensen MA, Hua Y, et al: SRSF1-regulated alternative splicing in breast cancer. Mol Cell. 60:105–117. 2015. View Article : Google Scholar : PubMed/NCBI
22	Moore MJ, Wang Q, Kennedy CJ and Silver PA: An alternative splicing network links cell-cycle control to apoptosis. Cell. 142:625–636. 2010. View Article : Google Scholar : PubMed/NCBI
23	Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C, Zhang J, Parysek LM and Knudsen KE: Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res. 70:3975–3984. 2010. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, López-Picazo JM, Torre W, Pio R and Montuenga LM: The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res. 16:4113–4125. 2010. View Article : Google Scholar : PubMed/NCBI
26	Anczuków O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, Muthuswamy SK and Krainer AR: The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 19:220–228. 2012. View Article : Google Scholar : PubMed/NCBI
27	Huang Z, Zhang L, Yi X and Yu X: Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma. Tumour Biol. 37:4359–4365. 2016. View Article : Google Scholar : PubMed/NCBI
28	Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, Christova S, Mitev V, Slavov C and Kaneva R: Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol. 34:189–200. 2015. View Article : Google Scholar : PubMed/NCBI
29	Ren Q, Liang J, Wei J, Basturk O, Wang J, Daniels G, Gellert LL, Li Y, Shen Y, Osman I, et al: Epithelial and stromal expression of miRNAs during prostate cancer progression. Am J Transl Res. 6:329–339. 2014.PubMed/NCBI
30	Verduci L, Simili M, Rizzo M, Mercatanti A, Evangelista M, Mariani L, Rainaldi G and Pitto L: microRNA (miRNA)-mediated interaction between leukemia/lymphoma-related factor (LRF) and alternative splicing factor/splicing factor 2 (ASF/SF2) affects mouse embryonic fibroblast senescence and apoptosis. J Biol Chem. 285:39551–39563. 2010. View Article : Google Scholar : PubMed/NCBI
31	Liu LL, Xie N, Sun S, Plymate S, Mostaghel E and Dong X: Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 33:3140–3150. 2014. View Article : Google Scholar : PubMed/NCBI
32	Busà R, Geremia R and Sette C: Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin. Nucleic Acids Res. 38:3005–3018. 2010. View Article : Google Scholar : PubMed/NCBI
33	Karni R, Hippo Y, Lowe SW and Krainer AR: The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci USA. 105:15323–15327. 2008. View Article : Google Scholar : PubMed/NCBI
34	Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, et al: The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 485:55–61. 2012. View Article : Google Scholar : PubMed/NCBI
35	Sinclair CS, Rowley M, Naderi A and Couch FJ: The 17q23 amplicon and breast cancer. Breast Cancer Res Treat. 78:313–322. 2003. View Article : Google Scholar : PubMed/NCBI